Actively Recruiting
NIS to Examine the Effectiveness and Safety of Durvalumab and Olaparib in Patients With Endometrial Cancer (DUOLife)
Led by AstraZeneca · Updated on 2026-05-12
150
Participants Needed
42
Research Sites
201 weeks
Total Duration
On this page
Sponsors
A
AstraZeneca
Lead Sponsor
N
North-Eastern German Society of Gynecological Oncology (NOGGO e.V.)
Collaborating Sponsor
AI-Summary
What this Trial Is About
This is a German multi-center, prospective, non-interventional study (NIS) to collect real-world clinical data in patients with primary advanced (FIGO stage III or IV) or recurrent endometrial cancer (EC) receiving first-line (1L) regimens with Carboplatin/Paclitaxel/Durvalumab (CPD) followed by maintenance therapy with durvalumab or durvalumab and olaparib in line with the applicable european summary of product characteristics (SmPC). Additionally, patient-reported outcomes after 1L treatment with CPD will be assessed.
CONDITIONS
Official Title
NIS to Examine the Effectiveness and Safety of Durvalumab and Olaparib in Patients With Endometrial Cancer (DUOLife)
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Women aged 18 years or older at screening
- Pathologically confirmed primary advanced (FIGO stage III or IV) epithelial endometrial cancer or recurrent disease unlikely to be cured requiring systemic therapy
- Intended or initiated first-line treatment with Carboplatin/Paclitaxel/Durvalumab followed by maintenance with durvalumab (dMMR cohort) or durvalumab and olaparib (pMMR cohort) as per product guidelines
- Eligible for durvalumab and/or olaparib treatment according to product characteristics
- Known mismatch repair (MMR) testing results of the tumor
- Willing and able to complete patient-reported outcome questionnaires
- Able to read and understand German, English, Arabic, Russian, or Turkish
- Signed written informed consent
You will not qualify if you...
- Received more than 2 cycles of first-line Carboplatin/Paclitaxel/Durvalumab
- Known allergy to carboplatin, paclitaxel, durvalumab, olaparib, or any excipients
- Pregnant or breastfeeding
- Unable to swallow oral medication
- Current or planned participation in an interventional clinical trial
- Current or planned systemic treatment for any tumor other than primary advanced or recurrent endometrial cancer
- Pathologically confirmed sarcoma
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 42 locations
1
Research Site
Amberg, Germany
Actively Recruiting
2
Research Site
Bad Nauheim, Germany
Actively Recruiting
3
Research Site
Bautzen, Germany
Actively Recruiting
4
Research Site
Berlin, Germany
Actively Recruiting
5
Research Site
Bielefeld, Germany
Actively Recruiting
6
Research Site
Borna, Germany
Actively Recruiting
7
Research Site
Bottrop, Germany
Actively Recruiting
8
Research Site
Brandenburg an der Havel, Germany
Actively Recruiting
9
Research Site
Braunschweig, Germany
Actively Recruiting
10
Research Site
Cologne, Germany
Actively Recruiting
11
Research Site
Dessau, Germany
Actively Recruiting
12
Research Site
Dresden, Germany
Actively Recruiting
13
Research Site
Ebersberg, Germany
Actively Recruiting
14
Research Site
Essen, Germany
Actively Recruiting
15
Research Site
Goslar, Germany
Actively Recruiting
16
Research Site
Greifswald, Germany
Actively Recruiting
17
Research Site
Gütersloh, Germany
Actively Recruiting
18
Research Site
Heilbronn, Germany
Actively Recruiting
19
Research Site
Homburg, Germany
Actively Recruiting
20
Research Site
Hösbach, Germany
Actively Recruiting
21
Research Site
Krefeld, Germany
Actively Recruiting
22
Research Site
Kulmbach, Germany
Actively Recruiting
23
Research Site
Landshut, Germany
Actively Recruiting
24
Research Site
Leipzig, Germany
Actively Recruiting
25
Research Site
Limburg, Germany
Actively Recruiting
26
Research Site
Lüneburg, Germany
Actively Recruiting
27
Research Site
Magdeburg, Germany
Actively Recruiting
28
Research Site
Mainz, Germany
Actively Recruiting
29
Research Site
München, Germany
Actively Recruiting
30
Research Site
Neuss, Germany
Actively Recruiting
31
Research Site
Nuremberg, Germany
Actively Recruiting
32
Research Site
Plauen, Germany
Actively Recruiting
33
Research Site
Rotenburg (Wümme), Germany
Actively Recruiting
34
Research Site
Siegen, Germany
Actively Recruiting
35
Research Site
Solingen, Germany
Actively Recruiting
36
Research Site
Torgau, Germany
Actively Recruiting
37
Research Site
Traunstein, Germany
Actively Recruiting
38
Research Site
Unna, Germany
Actively Recruiting
39
Research Site
Weningerode, Germany
Actively Recruiting
40
Research Site
Winnenden, Germany
Actively Recruiting
41
Research Site
Witten, Germany
Actively Recruiting
42
Research Site
Worms, Germany
Actively Recruiting
Research Team
A
AstraZeneca Clinical Study Information Center
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here